Literature DB >> 10817592

Developmental regulation of subunit composition of extrasynaptic NMDA receptors in neocortical neurones.

R Mohrmann1, H Hatt, K Gottmann.   

Abstract

NMDA receptors undergo drastic changes in their subunit composition during development of the mammalian neocortex. An increase in the expression of the NR2A subunit correlates with developmental changes in the properties of synaptic NMDA receptors. In this study, we investigated whether these developmental alterations are restricted to synaptic NMDA receptors or whether similar developmental changes also occur at extrasynaptic NMDA receptors. To analyse the properties of extrasynaptic receptors, glutamate-evoked ion currents mediated by extrasynaptic NMDA receptors were isolated by irreversibly blocking synaptic NMDA receptors with MK-801. Whole-cell ion currents mediated by extrasynaptic receptors showed developmental changes in their sensitivity against the NR2B subunit-specific antagonist ifenprodil similar to that of synaptic receptors. In summary, our results strongly suggest that NR2A subunit-containing NMDA receptors increasingly contribute also to extrasynaptic NMDA receptors during in vitro differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10817592     DOI: 10.1097/00001756-200004270-00012

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  11 in total

1.  The expression of NMDA receptor subunits in cerebral cortex and hippocampus is differentially increased by administration of endobain E, a Na+, K+-ATPase inhibitor.

Authors:  María Geraldina Bersier; Clara Peña; Georgina Rodríguez de Lores Arnaiz
Journal:  Neurochem Res       Date:  2007-08-08       Impact factor: 3.996

2.  Functional contributions of synaptically localized NR2B subunits of the NMDA receptor to synaptic transmission and long-term potentiation in the adult mouse CNS.

Authors:  Hideki Miwa; Masahiro Fukaya; Ayako M Watabe; Masahiko Watanabe; Toshiya Manabe
Journal:  J Physiol       Date:  2008-03-27       Impact factor: 5.182

Review 3.  Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment.

Authors:  E S Vizi; A Fekete; R Karoly; A Mike
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

4.  Genome-wide association study of severity in multiple sclerosis.

Authors: 
Journal:  Genes Immun       Date:  2011-06-09       Impact factor: 2.676

5.  HIV-1 Glycoprotein 120 Enhancement of N-Methyl-D-Aspartate NMDA Receptor-Mediated Excitatory Postsynaptic Currents: Implications for HIV-1-Associated Neural Injury.

Authors:  Yan Zhou; Jianuo Liu; Huangui Xiong
Journal:  J Neuroimmune Pharmacol       Date:  2016-12-22       Impact factor: 4.147

6.  Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors.

Authors:  H Shen; T Kihara; H Hongo; X Wu; W R Kem; S Shimohama; A Akaike; T Niidome; H Sugimoto
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

7.  Extrasynaptic targeting of NMDA receptors following D1 dopamine receptor activation and cocaine self-administration.

Authors:  Pavel I Ortinski; Jill R Turner; R Christopher Pierce
Journal:  J Neurosci       Date:  2013-05-29       Impact factor: 6.167

8.  Enhancement of NMDA receptor-mediated excitatory postsynaptic currents by gp120-treated macrophages: implications for HIV-1-associated neuropathology.

Authors:  Jianming Yang; Dehui Hu; Jianxun Xia; Jianuo Liu; Gang Zhang; Howard E Gendelman; Nawal M Boukli; Huangui Xiong
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-10       Impact factor: 4.147

Review 9.  Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity.

Authors:  Koji Yashiro; Benjamin D Philpot
Journal:  Neuropharmacology       Date:  2008-08-08       Impact factor: 5.250

10.  Glutamate neurocircuitry: theoretical underpinnings in schizophrenia.

Authors:  Thomas L Schwartz; Shilpa Sachdeva; Stephen M Stahl
Journal:  Front Pharmacol       Date:  2012-11-26       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.